Literature DB >> 15378523

Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease.

Carmela Ricciardelli1, Catherine S Choong, Grant Buchanan, Suchindra Vivekanandan, Petra Neufing, Jürgen Stahl, Villis R Marshall, David J Horsfall, Wayne D Tilley.   

Abstract

BACKGROUND: Although up to 30% of men who undergo radical prostatectomy for clinically organ-confined prostate cancer will relapse with disseminated disease, currently it is not possible to predict these patients.
METHODS: Androgen receptor (AR) immunoreactivity in stromal and epithelial compartments of tumor foci was evaluated by video image analysis in 53 radical prostatectomy specimens. Kaplan-Meier and Cox Regression analyses were used to determine whether AR immunostaining was related to rate and risk of relapse, respectively.
RESULTS: Ninety-eight percent (52/53) of the tumors contained AR positive malignant epithelial cells. Kaplan-Meier analysis indicated that patients with high AR levels (>64% AR positive nuclear area) in the malignant epithelial cells or low AR levels (<or=45% AR positive nuclear area) in the peritumoral stroma cells, were more likely to relapse earlier following radical prostatectomy. The shortest time to relapse and the highest relapse rate was for patients with both high AR in the malignant epithelial cells and low AR in the peritumoral stromal cells.
CONCLUSIONS: These findings suggest that AR is an important determinant of disease relapse in early stage prostate cancer, and that altered AR levels in the malignant epithelial cells or in the peritumoral stroma is indicative of non-organ confined prostate cancer. Copyright (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15378523     DOI: 10.1002/pros.20154

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  30 in total

Review 1.  Interaction of prostate carcinoma-associated fibroblasts with human epithelial cell lines in vivo.

Authors:  Takeshi Sasaki; Omar E Franco; Simon W Hayward
Journal:  Differentiation       Date:  2017-07-20       Impact factor: 3.880

2.  Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE).

Authors:  Eric W Deutsch; Catherine A Ball; Jules J Berman; G Steven Bova; Alvis Brazma; Roger E Bumgarner; David Campbell; Helen C Causton; Jeffrey H Christiansen; Fabrice Daian; Delphine Dauga; Duncan R Davidson; Gregory Gimenez; Young Ah Goo; Sean Grimmond; Thorsten Henrich; Bernhard G Herrmann; Michael H Johnson; Martin Korb; Jason C Mills; Asa J Oudes; Helen E Parkinson; Laura E Pascal; Nicolas Pollet; John Quackenbush; Mirana Ramialison; Martin Ringwald; David Salgado; Susanna-Assunta Sansone; Gavin Sherlock; Christian J Stoeckert; Jason Swedlow; Ronald C Taylor; Laura Walashek; Anthony Warford; David G Wilkinson; Yi Zhou; Leonard I Zon; Alvin Y Liu; Lawrence D True
Journal:  Nat Biotechnol       Date:  2008-03       Impact factor: 54.908

3.  Vitamin K2, a menaquinone present in dairy products targets castration-resistant prostate cancer cell-line by activating apoptosis signaling.

Authors:  Subramanyam Dasari; Angela Lincy Prem Antony Samy; Andre Kajdacsy-Balla; Maarten C Bosland; Gnanasekar Munirathinam
Journal:  Food Chem Toxicol       Date:  2018-02-09       Impact factor: 6.023

Review 4.  Therapeutic targeting of the prostate cancer microenvironment.

Authors:  Maria Karlou; Vassiliki Tzelepi; Eleni Efstathiou
Journal:  Nat Rev Urol       Date:  2010-09       Impact factor: 14.432

5.  Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer.

Authors:  Imtiaz A Siddiqui; Mohammad Asim; Bilal B Hafeez; Vaqar M Adhami; Rohinton S Tarapore; Hasan Mukhtar
Journal:  FASEB J       Date:  2010-12-21       Impact factor: 5.191

6.  Androgen receptors expressed by prostatic stromal cells obtained from younger versus older males exhibit opposite roles in prostate cancer progression.

Authors:  You-Yi Lu; Bo Jiang; Fu-Jun Zhao; Di Cui; Qi Jiang; Jun-Jie Yu; En-Hui Li; Xiao-Hai Wang; Bang-Min Han; Shu-Jie Xia
Journal:  Asian J Androl       Date:  2013-06-24       Impact factor: 3.285

Review 7.  Stroma-epithelium crosstalk in prostate cancer.

Authors:  Yi-Nong Niu; Shu-Jie Xia
Journal:  Asian J Androl       Date:  2008-12-22       Impact factor: 3.285

Review 8.  A role for the androgen-receptor in clinically localized and advanced prostate cancer.

Authors:  James L Mohler
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

Review 9.  Cancer associated fibroblasts in cancer pathogenesis.

Authors:  Omar E Franco; Aubie K Shaw; Douglas W Strand; Simon W Hayward
Journal:  Semin Cell Dev Biol       Date:  2009-11-05       Impact factor: 7.727

10.  Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells.

Authors:  Donald J Vander Griend; Jason D'Antonio; Bora Gurel; Lizamma Antony; Angelo M Demarzo; John T Isaacs
Journal:  Prostate       Date:  2010-01-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.